Published in Breast Cancer Res on March 05, 2010
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol (2010) 1.17
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res (2011) 1.03
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res (2014) 1.03
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat (2010) 1.01
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res (2010) 0.95
Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J Neurooncol (2015) 0.90
Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. Mol Cell Proteomics (2015) 0.87
DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol (2015) 0.84
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. Cancer Sci (2011) 0.82
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res (2016) 0.79
Over expression of hRad9 protein correlates with reduced chemosensitivity in breast cancer with administration of neoadjuvant chemotherapy. Sci Rep (2014) 0.79
A novel ruthenium(II)-polypyridyl complex inhibits cell proliferation and induces cell apoptosis by impairing DNA damage repair. J Chemother (2013) 0.79
Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med (2016) 0.78
Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol (2017) 0.77
Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers. Oncotarget (2016) 0.76
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. Biomed Res Int (2016) 0.75
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci (2017) 0.75
Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. World J Gastroenterol (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem (2004) 14.93
The DNA damage response: ten years after. Mol Cell (2007) 11.80
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell (2007) 9.25
RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell (2007) 8.71
Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol (2003) 8.55
Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science (2007) 7.61
RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell (2009) 6.89
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science (2007) 6.77
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science (2007) 6.70
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell (2009) 5.96
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell (1997) 5.92
Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science (2007) 5.88
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell (2003) 5.26
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A (2007) 4.75
Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev (2006) 4.18
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science (1999) 3.47
Human DNA polymerase eta promotes DNA synthesis from strand invasion intermediates of homologous recombination. Mol Cell (2005) 3.16
HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature (2008) 3.14
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol (2006) 3.01
Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis. Mol Cell (2005) 2.88
RAD18 transmits DNA damage signalling to elicit homologous recombination repair. Nat Cell Biol (2009) 2.67
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
The RING finger protein RNF8 recruits UBC13 for lysine 63-based self polyubiquitylation. J Cell Biochem (2006) 2.03
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res (2007) 1.68
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer (2006) 1.65
Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Mol Cell (2007) 1.49
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res (2007) 1.48
Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem (2004) 1.39
Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res (2003) 1.34
Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol Cell (2003) 1.33
The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div (2008) 1.21
Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry (1990) 1.20
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol (2005) 1.06
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol (2005) 1.05
Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. Cancer Chemother Pharmacol (2009) 0.86
Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells. Cancer Res (1989) 0.83
Cancer: crossing over to drug resistance. Nature (2008) 0.82
Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet (2003) 7.98
Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat Cell Biol (2004) 3.72
Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci U S A (2003) 3.37
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol (2012) 2.25
A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol Cell (2005) 2.15
Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem (2003) 1.97
HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res (2004) 1.74
BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res (2009) 1.72
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat (2005) 1.71
Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci (2007) 1.57
Overexpression of heat shock protein 27 in squamous cell carcinoma of the uterine cervix: a proteomic analysis using archival formalin-fixed, paraffin-embedded tissues. Hum Pathol (2008) 1.55
Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat (2007) 1.50
The pathogenesis and clinical significance of a high-intensity zone (HIZ) of lumbar intervertebral disc on MR imaging in the patient with discogenic low back pain. Eur Spine J (2005) 1.48
Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J (2006) 1.45
Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer (2006) 1.42
Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem (2004) 1.39
Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma. Pathol Int (2010) 1.39
Possible pathogenesis of painful intervertebral disc degeneration. Spine (Phila Pa 1976) (2006) 1.35
A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat (2011) 1.31
Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins. J Biol Chem (2002) 1.29
Essential role of synoviolin in embryogenesis. J Biol Chem (2004) 1.28
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer (2013) 1.26
Ubiquitin and breast cancer. Oncogene (2004) 1.26
Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer (2008) 1.25
Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res (2012) 1.23
HERC2 is an E3 ligase that targets BRCA1 for degradation. Cancer Res (2010) 1.23
The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div (2008) 1.21
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res (2003) 1.21
Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci (2009) 1.20
Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci (2010) 1.18
Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene (2003) 1.13
Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res (2006) 1.13
A primary pulmonary glomus tumor: a case report and review of the literature. Case Rep Pathol (2012) 1.12
Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res (2005) 1.12
Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates. Cancer Res (2010) 1.10
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer (2008) 1.09
Menopausal status should be taken into consideration for patients with luminal a breast cancer in terms of the effect of differential biology on prognosis. J Clin Oncol (2013) 1.09
Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol (2007) 1.09
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res (2007) 1.08
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res Treat (2009) 1.07
Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett (2003) 1.05
Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer (2009) 1.05
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther (2011) 1.04
Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci (2009) 1.04
p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res (2006) 1.03
Estrogen receptor alpha mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women. Breast Cancer (2003) 1.02
Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry. Surg Today (2006) 1.02
No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol (2009) 1.01
Fusion of SPECT and multidetector CT images for accurate localization of pelvic sentinel lymph nodes in prostate cancer patients. J Nucl Med Technol (2005) 1.00
Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol (2006) 1.00
Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer (2009) 0.99
A DNA-damage selective role for BRCA1 E3 ligase in claspin ubiquitylation, CHK1 activation, and DNA repair. Curr Biol (2012) 0.99
ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer. Clin Cancer Res (2005) 0.99
Putative tumor suppressor EDD interacts with and up-regulates APC. Genes Cells (2007) 0.98
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci (2009) 0.98
Midkine in plasma as a novel breast cancer marker. Cancer Sci (2009) 0.98
Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer. Proc Natl Acad Sci U S A (2014) 0.97
Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol (2007) 0.97
The expression of tumor necrosis factor-α and CD68 in high-intensity zone of lumbar intervertebral disc on magnetic resonance image in the patients with low back pain. Spine (Phila Pa 1976) (2011) 0.97
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol (2006) 0.97
Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer (2012) 0.94
Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci (2007) 0.93
A case report of paraneoplastic neurological syndrome associated with occult breast cancer. Breast Cancer (2006) 0.93
Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Ann Surg Oncol (2012) 0.92
Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol (2010) 0.92
The BRCA1 ubiquitin ligase and homologous recombination repair. FEBS Lett (2011) 0.91
Intraductal papilloma: features on MR ductography using a microscopic coil. AJR Am J Roentgenol (2006) 0.91
High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. Breast Cancer (2012) 0.91
Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci (2004) 0.90
Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression. Breast Cancer Res Treat (2011) 0.90
Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer Res (2005) 0.90
BRCA1 ubiquitinates RPB8 in response to DNA damage. Cancer Res (2007) 0.90
Validity of sentinel lymph node concept for patients with prostate cancer. J Urol (2004) 0.89
Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer (2009) 0.89
Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer. BMC Cancer (2008) 0.89
Chemical radiculitis. Pain (2006) 0.89
Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat (2014) 0.88
Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci (2015) 0.88
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast. Breast Cancer Res (2003) 0.88
Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. Int J Clin Oncol (2008) 0.87
High-resolution MRI in detecting subareolar breast abscess. AJR Am J Roentgenol (2007) 0.87